WORKSHOP A: 9.00-12.00

Overviewing Payload Classes & Exploring Potency & Toxicity Concerns: What is the Next Frontier in ADC Payloads?

  • Lenka Sadilkova Head of Preclinical Research and Development, Mablink, a Wholly Owned Subsidary of Eli Lily & Company


ADCs have demonstrated impressive clinical efficacy in several tumor types, however resistance and a competitive environment for some of these clinically validated payloads is driving drug developers to identify novel mechanisms of action and optimize payload structure with analogues of traditional payloads.

With such a wide scope of development of ADC payloads following huge successes from the lower potency topoisomerase payloads, how can we predict what the next big thing for ADC payloads is?

Join this session to:

  • Uncover emerging trends in ADC payloads to develop the next generation of ADC payloads
  • Explore the most novel MoAs that are entering pre-clinical development, and consider the feasibility of these payloads to progress
  • Assess the current unmet needs and gaps in ADC payload discovery, design and development

LUNCH: 12.00-1.00

Rational Combination of ADC With Chemotherapeutic & Immunotherapeutic Agents


Antibody Drug Conjugates are the leading modality of cancer therapies that has revolutionized the treatment paradigm of solid tumors. With the rapidly evolving clinical landscape, the number of combination trials involving ADCs have burgeoned in the last few years. Immunotherapeutic agents such as Immune-checkpoint inhibitors and T cell engagers are rapidly emerging therapies for solid tumor targeting. This workshop will allow you to understand the preclinical characterization which is critical for understanding the potential synergism and enable prudent choice of rational clinical combinations of ADCs.

Join this session to gain:

  • An evaluation of the evolution of conjugation technologies, linkers and payloads
  • A technical understanding of approaches in selecting a combination partner to broaden therapeutic index and achieve durable response
  • An outline of toxicity concerns and considerations for combinations
  • An overview of the current status of chemotherapeutics and clinical landscape of ADC combinations as well as the current status of Immunotherapeutic agents and clinical landscape of ADC combinations